Bacterial Infections Therapeutics
1. Aemcolo patent expiration
Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8741948 | COSMO | Oral antimicrobial pharmaceutical compositions |
May, 2025
(9 months ago) | |
| US8529945 | COSMO | Oral antimicrobial pharmaceutical compositions |
May, 2025
(9 months ago) | |
| US8263120 | COSMO | Oral antimicrobial pharmaceutical compositions |
May, 2025
(9 months ago) | |
| US8486446 | COSMO | Oral antimicrobial pharmaceutical compositions |
May, 2025
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 16, 2028 |
Drugs and Companies using RIFAMYCIN SODIUM ingredient
NCE-1 date: 16 November, 2022
Market Authorisation Date: 16 November, 2018
Dosage: TABLET, DELAYED RELEASE
More Information on Dosage
AEMCOLO family patents
2. Avelox patent expiration
Treatment: Method of combating bacteria in a patient
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6610327 | BAYER | Pharmaceutical moxifloxacin preparation |
Oct, 2019
(6 years ago) | |
| US5849752 | BAYER | Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification |
Dec, 2016
(9 years ago) | |
| US5607942 | BAYER | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar, 2014
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-185) | Sep 27, 2019 |
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 December, 1999
Dosage: TABLET
How can I launch a generic of AVELOX before it's drug patent expiration?
More Information on Dosage
AVELOX family patents
3. Baxdela patent
expiration
Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults; Treating an acute bacterial skin and skin structure infection (absssi) in an overwe...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8497378 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(3 years from now) | |
| US9539250 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(4 months ago) | |
| US8871938 | MELINTA | Process for making quinolone compounds |
Sep, 2029
(3 years from now) | |
| US7728143 | MELINTA | Salt and crystalline forms thereof of a drug |
Jun, 2031
(5 years from now) | |
| US8273892 | MELINTA | Salt and crystalline forms thereof of a drug |
Aug, 2026
(5 months from now) | |
| USRE46617 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8252813 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2026
(7 months from now) | |
| US8648093 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(4 months ago) | |
| US12036219 | MELINTA | Methods of treating infections in overweight and obese patients using antibiotics |
Jun, 2034
(8 years from now) | |
| US9200088 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9750822 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US7635773 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US8410077 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9493582 | MELINTA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(7 years from now) | |
| US12138257 | MELINTA | Antimicrobial compositions |
May, 2032
(6 years from now) | |
| US8969569 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 19, 2022 |
| New Indication(I-815) | Oct 24, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: 19 June, 2021
Market Authorisation Date: 19 June, 2017
Dosage: POWDER; TABLET
More Information on Dosage
BAXDELA family patents
4. Blujepa patent expiration
Treatment: Treatment of adult and pediatric patients 12 years of age and older weighing at least 45 kg who have limited or no alternative options with uncomplicated urogenital gonorrhea caused by susceptible str...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8389524 | GLAXOSMITHKLINE | Tricyclic nitrogen containing compounds as antibacterial agents |
Feb, 2029
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10702521 | GLAXOSMITHKLINE | Methods For Treating Neisseria Gonorrhoeae Infection With Substituted 1,2-Dihydro-2A,5,8A-Triazaacenaphthylene-3,8-Diones |
Aug, 2035
(9 years from now) | |
| US11229646 | GLAXOSMITHKLINE | Method For Treating Gonorrhea With (2R)-2-({4-[(3,4-Dihydro-2H-Pyrano[2,3-C]Pyridin-6-Ylmethyl)Amino]-1-Piperidinyl}Methyl)-1,2-Dihydro-3H,8H-2A,5,8A-Triazaacenaphthylene-3,8-Dione |
Aug, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-978) | Dec 11, 2028 |
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2030 |
| Generating Antibiotic Incentives Now(GAIN) | Mar 25, 2035 |
Drugs and Companies using GEPOTIDACIN MESYLATE ingredient
NCE-1 date: 25 March, 2029
Market Authorisation Date: 25 March, 2025
Dosage: TABLET
More Information on Dosage
BLUJEPA family patents
5. Cubicin patent expiration
Treatment: Method of treating bacterial infections; Method for treating bacterial infection; Treatment of the following infections: complicated skin an...
CUBICIN's oppositions filed in EPO
CUBICIN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9138456 | CUBIST | Lipopeptide compositions and related methods |
Nov, 2030
(4 years from now) | |
| US6468967 | CUBIST | Methods for administration of antibiotics |
Sep, 2019
(6 years ago) | |
| US8058238 | CUBIST | High purity lipopeptides |
Nov, 2020
(5 years ago) | |
| US6852689 | CUBIST | Methods for administration of antibiotics |
Sep, 2019
(6 years ago) | |
| US8129342 | CUBIST | High purity lipopeptides |
Nov, 2020
(5 years ago) | |
| USRE39071 | CUBIST | Anhydro-and isomer-a-21978c cyclic peptides |
Jun, 2016
(9 years ago) | |
| US8003673 | CUBIST | Daptomycin for the treatment of biofilm and catheter salvage |
Sep, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 29, 2020 |
| M(M-211) | Sep 01, 2020 |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 12 September, 2003
Dosage: POWDER
How can I launch a generic of CUBICIN before it's drug patent expiration?
More Information on Dosage
CUBICIN family patents
6. Doribax patent expiration
Treatment: Method of treating bacterial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8247402 | SHIONOGI | Crystal form of pyrrolidylthiocarbapenem derivative |
Mar, 2021
(4 years ago) | |
| US5317016 | SHIONOGI | Pyrrolidylthiocarbapenem derivative |
Jun, 2015
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
Drugs and Companies using DORIPENEM ingredient
NCE-1 date: 13 October, 2011
Market Authorisation Date: 05 October, 2010
Dosage: INJECTABLE
How can I launch a generic of DORIBAX before it's drug patent expiration?
More Information on Dosage
DORIBAX family patents
7. Fetroja patent expiration
Treatment: Method of treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) comprising administering cefiderocol sulfate tosylate
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9238657 | SHIONOGI | Cephalosporin having catechol group |
Nov, 2033
(7 years from now) | |
| US10004750 | SHIONOGI | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof |
Sep, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949982 | SHIONOGI | Preparation containing cephalosporin having a catechol moiety |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-844) | Sep 25, 2023 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 14, 2029 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Dosage: POWDER
More Information on Dosage
FETROJA family patents
8. Invanz patent expiration
Treatment: Treatment of bacterial infectious disease
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5478820 (Pediatric) | MERCK | Antibiotic compounds |
May, 2016
(9 years ago) | |
| US5652233 | MERCK | Antibiotic compounds |
Feb, 2013
(13 years ago) | |
|
US5952323 (Pediatric) | MERCK | Carbapenem antibiotic |
Nov, 2017
(8 years ago) | |
| US7342005 | MERCK | Antibiotic compounds |
Feb, 2013
(13 years ago) | |
|
US7342005 (Pediatric) | MERCK | Antibiotic compounds |
Aug, 2013
(12 years ago) | |
|
US5652233 (Pediatric) | MERCK | Antibiotic compounds |
Aug, 2013
(12 years ago) | |
| US5478820 | MERCK | Antibiotic compounds |
Nov, 2015
(10 years ago) | |
| US5952323 | MERCK | Carbapenem antibiotic |
May, 2017
(8 years ago) | |
Drugs and Companies using ERTAPENEM SODIUM ingredient
Market Authorisation Date: 21 November, 2001
Dosage: INJECTABLE
How can I launch a generic of INVANZ before it's drug patent expiration?
More Information on Dosage
INVANZ family patents
9. Ketek patent expiration
Treatment: Treatment of community acquired pneumonia, acute exacerbation of chronic bronchitis, and acute bacterial sinusitis caused by susceptible strains of designated microorganisms in patients 18 years and o...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USD459798 | SANOFI | Pill tablet |
Sep, 2015
(10 years ago) | |
| US5635485 | SANOFI | Erythromycin compounds |
Apr, 2018
(7 years ago) | |
Drugs and Companies using TELITHROMYCIN ingredient
Market Authorisation Date: 09 February, 2005
Dosage: TABLET
More Information on Dosage
KETEK family patents
10. Nuzyra patent expiration
Treatment: Treatment of bacterial skin and skin structure infections; Treatment of community acquired bacterial pneumonia; Treatment of bacterial skin and skin structure infection; Treatment of subjects having b...
NUZYRA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326696 | PARATEK | Amino-methyl substituted tetracycline compounds |
Sep, 2023
(2 years ago) | |
| US7553828 | PARATEK | 9-aminomethyl substituted minocycline compounds |
Jun, 2025
(8 months ago) | |
| US8383610 | PARATEK | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
Sep, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9365500 | PARATEK | 9-aminomethyl substituted minocycline compounds |
Jun, 2021
(4 years ago) | |
| US10383884 | PARATEK | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(11 years from now) | |
| US9724358 | PARATEK | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US10124014 | PARATEK | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US10111890 | PARATEK | 9-aminomethyl minocycline compounds and uses thereof |
Aug, 2037
(11 years from now) | |
| US10835542 | PARATEK | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(11 years from now) | |
| US9265740 | PARATEK | Minocycline compounds and methods of use thereof |
Mar, 2029
(3 years from now) | |
| US9314475 | PARATEK | Oral and injectable formulations of tetracycline compounds |
Mar, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 02, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 02, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 02 October, 2022
Market Authorisation Date: 02 October, 2018
Dosage: TABLET; POWDER
More Information on Dosage
NUZYRA family patents
11. Orbactiv patent expiration
Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections; Treatment of acute bacterial skin and skin structure infection...
ORBACTIV's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5840684 | MELINTA | Glycopeptide antibiotic derivatives |
Nov, 2020
(5 years ago) | |
| US5998581 | MELINTA | Reductive alkylation of glycopeptide antibiotics |
Nov, 2017
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420592 | MELINTA | Methods of treatment using single doses of oritavancin |
Aug, 2029
(3 years from now) | |
| US9682061 | MELINTA | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(4 years from now) | |
| US9649352 | MELINTA | High purity oritavancin and method of producing same |
Jul, 2035
(9 years from now) | |
| US12514899 | MELINTA | Methods Of Treatment Using Single Doses Of Oritavancin |
Aug, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 06 August, 2014
Dosage: POWDER
More Information on Dosage
ORBACTIV family patents
12. Sivextro patent expiration
Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8426389 | CUBIST | Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Dec, 2030
(4 years from now) | |
| US8420676 | CUBIST | Oxazolidinone derivatives |
Feb, 2028
(2 years from now) | |
| US9624250 | CUBIST | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(3 years from now) | |
| US7816379 | CUBIST | Oxazolidinone derivatives |
Jun, 2028
(2 years from now) | |
| US10442829 | CUBIST | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9988406 | CUBIST | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(3 years from now) | |
| US10065947 | CUBIST | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Feb, 2030
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 20, 2024 |
| New Patient Population(NPP) | Apr 04, 2028 |
Drugs and Companies using TEDIZOLID PHOSPHATE ingredient
NCE-1 date: 20 June, 2018
Market Authorisation Date: 20 June, 2014
Dosage: TABLET; POWDER
More Information on Dosage
SIVEXTRO family patents
13. Solosec patent expiration
Treatment: Treatment of trichomoniasis in patients 12 years of age and older; Treatment of bacterial vaginosis in adult women; Treatment of bacterial vaginosis in female patients 12 years of age and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12280037 | EVOFEM | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof |
Dec, 2041
(15 years from now) | |
| US10849884 | EVOFEM | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US10857133 | EVOFEM | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US11324721 | EVOFEM | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(9 years from now) | |
| US10335390 | EVOFEM | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US11602522 | EVOFEM | Secnidazole for use in the treatment of sexually transmitted infection |
Sep, 2035
(9 years from now) | |
| US11000508 | EVOFEM | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(9 years from now) | |
| US11000507 | EVOFEM | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US11020377 | EVOFEM | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US10682338 | EVOFEM | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US11684607 | EVOFEM | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2022 |
| New Indication(I-866) | Jun 30, 2024 |
| New Patient Population(NPP) | Jan 26, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 15, 2027 |
Drugs and Companies using SECNIDAZOLE ingredient
NCE-1 date: 15 September, 2021
Market Authorisation Date: 15 September, 2017
Dosage: GRANULE
More Information on Dosage
SOLOSEC family patents
14. Spectracef patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5958915 | VANSEN | Antibacterial composition for oral administration |
Oct, 2016
(9 years ago) | |
Drugs and Companies using CEFDITOREN PIVOXIL ingredient
Market Authorisation Date: 29 August, 2001
Dosage: TABLET
More Information on Dosage
SPECTRACEF family patents
15. Tygacil patent expiration
Treatment: Method of treating bacterial infections
TYGACIL's oppositions filed in EPO
TYGACIL IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE40183 | PF PRISM CV | 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
Apr, 2016
(9 years ago) | |
| USRE40086 | PF PRISM CV | Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines |
Jun, 2013
(12 years ago) | |
| US7879828 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Feb, 2029
(2 years from now) | |
| US9254328 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(19 days from now) | |
| US8975242 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Oct, 2028
(2 years from now) | |
| US8372995 | PF PRISM CV | Crystalline solid forms of tigecycline and methods of preparing same |
Oct, 2030
(4 years from now) | |
| US9694078 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(19 days from now) | |
| US10588975 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(19 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-586) | Mar 20, 2012 |
| New Indication(I-587) | Mar 20, 2012 |
| New Indication(I-588) | Mar 20, 2012 |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 15 June, 2005
Dosage: POWDER
More Information on Dosage
TYGACIL family patents
16. Vibativ patent expiration
Treatment: Method for treating bacterial infection; Method of treating a staphylococcal infection; Method of treating bacterial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7531623 | CUMBERLAND | Hydrochloride salts of a glycopeptide phosphonate derivative |
Jan, 2027
(10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7544364 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May, 2021
(4 years ago) | |
| US6872701 | CUMBERLAND | Glycopeptide phosphonate derivatives |
Jun, 2021
(4 years ago) | |
| US8158580 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May, 2021
(4 years ago) | |
| US6635618 | CUMBERLAND | Glycopeptide phosphonate derivatives |
Sep, 2023
(2 years ago) | |
| US7008923 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| US7700550 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| US7208471 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| US8101575 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| US6858584 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
Aug, 2022
(3 years ago) | |
| US7351691 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 11, 2014 |
| New Indication(I-673) | Jun 21, 2016 |
Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 11 September, 2013
Market Authorisation Date: 11 September, 2009
Dosage: POWDER
More Information on Dosage
VIBATIV family patents
17. Xenleta patent expiration
Treatment: Treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6753445 | HONG KONG | Pleuromutilin derivatives having antibacterial activity |
Jul, 2021
(4 years ago) | |
| US8071643 | HONG KONG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2033
(7 years from now) | |
| US8153689 | HONG KONG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2028
(2 years from now) | |
| US9120727 | HONG KONG | Process for the preparation of pleuromutilins |
May, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12121582 | HONG KONG | Injectable pharmaceutical formulations of lefamulin |
Jun, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 19, 2029 |
Drugs and Companies using LEFAMULIN ACETATE ingredient
NCE-1 date: 20 August, 2023
Market Authorisation Date: 19 August, 2019
Dosage: TABLET; SOLUTION
More Information on Dosage
XENLETA family patents
18. Xifaxan patent expiration
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; Reduction in a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (he) episode; ...
XIFAXAN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8741904 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(5 days from now) | |
| US8835452 | SALIX | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US8193196 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Sep, 2027
(1 year, 6 months from now) | |
| US8158781 | SALIX | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US7612199 | SALIX | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US7902206 | SALIX | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US7045620 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(1 year, 8 months ago) | |
| US7906542 | SALIX | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10456384 | SALIX | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US10335397 | SALIX | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US9421195 | SALIX | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US8946252 | SALIX | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US7452857 | SALIX | Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US8829017 | SALIX | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US8642573 | SALIX | Methods of treating hepatic encephalopathy |
Oct, 2029
(3 years from now) | |
| US10314828 | SALIX | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US7915275 | SALIX | Use of polymorphic forms of rifaximin for medical preparations |
Feb, 2025
(11 months ago) | |
| US7605240 | SALIX | Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US7935799 | SALIX | Methods of treating diarrhea caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US10709694 | SALIX | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US10765667 | SALIX | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US8969398 | SALIX | Methods of treating hepatic encephalopathy |
Oct, 2029
(3 years from now) | |
| US6861053 | SALIX | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US8518949 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(5 days from now) | |
| US9629828 | SALIX | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US9271968 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(5 days from now) | |
| US8158781 | SALIX | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US8158644 | SALIX | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US7612199 | SALIX | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US8853231 | SALIX | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US7045620 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(1 year, 8 months ago) | |
| US8193196 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Sep, 2027
(1 year, 6 months from now) | |
| US10703763 | SALIX | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(5 days from now) | |
| US7718608 | SALIX | Methods of treating a subject suffering from irritable bowel syndrome |
Aug, 2019
(6 years ago) | |
| US8309569 | SALIX | Methods for treating diarrhea-associated irritable bowel syndrome |
Jul, 2029
(3 years from now) | |
| US7902206 | SALIX | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 8 months ago) | |
| US7906542 | SALIX | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(8 months ago) | |
| US11564912 | SALIX | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US7928115 | SALIX | Methods of treating travelers diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US11779571 | SALIX | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 24, 2013 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
| New Indication(I-709) | May 27, 2018 |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 24 March, 2010
Dosage: TABLET
How can I launch a generic of XIFAXAN before it's drug patent expiration?
More Information on Dosage
XIFAXAN family patents
19. Zemdri patent expiration
Treatment: Method of using plazomicin to treat bacterial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8383596 | CIPLA | Antibacterial aminoglycoside analogs |
Jun, 2032
(6 years from now) | |
| US9688711 | CIPLA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9266919 | CIPLA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| US8822424 | CIPLA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 25, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 25, 2028 |
Drugs and Companies using PLAZOMICIN SULFATE ingredient
NCE-1 date: 25 June, 2022
Market Authorisation Date: 25 June, 2018
Dosage: SOLUTION
More Information on Dosage
ZEMDRI family patents
20. Zyvox patent expiration
Treatment: Treatment of microbial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6514529 | PFIZER | Oxazolidinone tablet formulation |
Mar, 2021
(4 years ago) | |
| US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(5 years ago) | |
|
US6559305 (Pediatric) | PFIZER | Linezolid—crystal form II |
Jul, 2021
(4 years ago) | |
| US5688792 | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
Nov, 2014
(11 years ago) | |
|
US5688792 (Pediatric) | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
May, 2015
(10 years ago) | |
|
US6514529 (Pediatric) | PFIZER | Oxazolidinone tablet formulation |
Sep, 2021
(4 years ago) | |
Drugs and Companies using LINEZOLID ingredient
Market Authorisation Date: 18 April, 2000
Dosage: SOLUTION; TABLET; FOR SUSPENSION
How can I launch a generic of ZYVOX before it's drug patent expiration?
More Information on Dosage
ZYVOX family patents